Alivexis is a biotechnology company that engages in the research and development of custom medicine for the pharmaceutical industry.
Alivexis has raised $20.4M in total funding. The most recent round was Series C. The last funding was announced in March 2022.
Alivexis's investors include SBI Investment, Mizuho Capital, SMBC Venture Capital, Fast Track Initiative, Inc., UTokyo Innovation Platform.
Alivexis is headquartered in Minato, Japan.
Alivexis is a biotechnology company that engages in the research and development of custom medicine for the pharmaceutical industry.
Alivexis is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alivexis — Funding & Investors." VCBacked, March 1, 2022, https://www.vcbacked.co/company/alivexis. Accessed September 29, 2026.
VCBacked. (2022). Alivexis — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/alivexis
{{cite web |title=Alivexis — Funding & Investors |url=https://www.vcbacked.co/company/alivexis |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated